$242.99
-2.45-1.00%
Pre-Market: 7:48 AM EDT
Alnylam Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Alnylam Pharmaceuticals using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Sep 2024 | 2024-10-31 | $-0.50 | $-0.93 | 46.2 % |
Jun 2024 | 2024-08-01 | $0.56 | $-1.08 | 151.8 % |
Mar 2024 | 2024-05-02 | $-0.16 | $-1.18 | 86.4 % |
Dec 2023 | 2024-02-15 | $-0.77 | $-1.33 | 42.1 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Sep 2024 | 2024-10-31 | $500.92M | $533.10M | -6.04 % |
Jun 2024 | 2024-08-01 | $659.83M | $444.11M | 48.6 % |
Mar 2024 | 2024-05-02 | $494.33M | $427.33M | 15.7 % |
Dec 2023 | 2024-02-15 | $439.72M | $442.90M | -0.72 % |
Alnylam Pharmaceuticals (ALNY) is scheduled to report earnings on February 13, 2025. The last reported earnings were for reported on October 31, 2024 for Q3.
The Actual EPS was $-0.50, which beat the estimate of $-0.93.
The Actual Revenue was $500.9M, which missed the estimate of $533.1M.
Browse earnings estimates, EPS, and revenue on all stocks.